Unity Bio receives Nasdaq deficiency notice for bid price and equity; shares below $1.00

Unity Biotechnology, Inc.

Closing bid price below $1.00 for 30 consecutive business days; 180-day cure period until Dec 15, 2025.
Previously (Mar 2025) notified for equity below $10M minimum for Nasdaq Global Select; compliance plan submitted.
Company applied to transfer to Nasdaq Capital Market on June 9, 2025.
Failure to regain compliance may result in delisting; no assurance of cure.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.